

INESSS invitations to submit a drug listing or re-evaluation request

When the Institut national d'excellence en santé et en services sociaux (INESSS) receives formal requests from patients, Quebec healthcare professionals, the MSSS or the RAMQ for the evaluation or re-evaluation of a drug, or a revision of reimbursement indications that it considers justified, it systematically invites the relevant manufacturers to submit a listing or re-evaluation request according to established standards, or to formally justify any refusal to do so. INESSS may also initiate such invitations when issues are identified regarding drug reimbursement in Quebec (e.g. product listing withdrawal).

Should a manufacturer fail to return a formal response (i.e. either a refusal or an approval) within 30 days following the invitation, the request status will automatically be changed to "Refused".

Invitations in 2023

Trademark	Common name	Name of the manufacturer	Indication	Type of request	Request status	Invitation date
Campral	acamprosate	Viartis	Alcoholic abstinence	Re-evaluation	Accepted - Evaluated	14-11-2023
Phenobarbital sodium injection	phenobarbital sodium	Sandoz	Continuous palliative sedation	Listing request	Accepted - Evaluated	13-11-2023
Eprex	epoetin alfa	Janss. Inc	Perioperative anemia	New indication	Refused	16-10-2023
AA-Metoprolol SR	metoprolol	AA Pharma	Various indications	Listing request	Refused	03-10-2023
Ozurdex	dexamethasone	AbbVie	Diabetic macular edema	Re-evaluation	Accepted - Evaluated	25-09-2023
Esbriet	pirfenidone	Roche	Pulmonary fibrosis	Re-evaluation	Refused	18-09-2023
Sandoz Pirfenidone	pirfenidone	Sandoz	Pulmonary fibrosis	Re-evaluation	Refused	18-09-2023
pms-Pirfenidone	pirfenidone	Phmscience	Pulmonary fibrosis	Re-evaluation	Refused	18-09-2023
JAMP Pirfenidone	pirfenidone	Jamp	Pulmonary fibrosis	Re-evaluation	Refused	18-09-2023
Zyprexa IntraMuscular	olanzapine	Lilly	Psychotic disorders	Re-evaluation	Refused	15-09-2023
Actemra	tocilizumab	Roche	COVID-19	New indication	Refused	08-08-2023

Sotrovimab inj.	sotrovimab	GSK	COVID-19	New indication	Refused	08-08-2023
Veklury	remdésivir	Gilead	COVID-19	New indication	Accepted - Evaluated	08-08-2023
Xarelto	rivaroxaban	Bayer	Venous thromboembolism	New indication	Refused	04-08-2023
Silenor	doxepin	Paladin	Insomnia	New indication	Refused	04-08-2023
Actemra	tocilizumab	Roche	Giant cell arteritis	Re-evaluation	Refused	20-06-2023
Vectibix	panitumumab	Amgen	Colorectal cancer	Re-evaluation	Refused	09-06-2023
Xolair	omalizumab	Novartis	Nasal polyps	New indication	Refused	09-06-2023
Dupixent	dupilumab	SanofiAven	Nasal polyps	New indication	Refused	09-06-2023
Ozempic	semaglutide	N.Nordisk	Diabetes	Re-evaluation	Accepted - Evaluated	17-05-2023
Trulicity	dulaglutide	Lilly	Diabetes	Re-evaluation	Refused	17-05-2023
Stromectol	ivermectin	Merck	Strongyloidiasis	Listing request	Refused	10-05-2023
Opdivo	nivolumab	B.M.S.	Melanoma	Re-evaluation	Refused	10-05-2023
Natesto	testosterone	Acerus	Testosterone replacement therapy	Listing request	Refused	10-05-2023
Estalis	estradiol-17B / norethindrone	Sandoz	Hormone therapy	Re-evaluation	Refused	08-05-2023
Estradot	estradiol-17B	Sandoz	Hormone therapy	Re-evaluation	Refused	08-05-2023
Estradiol Derm	estradiol-17B	Sandoz	Hormone therapy	Re-evaluation	Refused	08-05-2023
Climara	estradiol-17B	Bayer	Hormone therapy	Re-evaluation	Refused	08-05-2023
Bijuva	estradiol hemihydrate	Knight	Hormone therapy	Listing request	Accepted - Evaluated	08-05-2023
Divigel	estradiol-17B	Search Phm	Hormone therapy	Re-evaluation	Refused	08-05-2023

Oesclim	estradiol-17B	Search Phm	Hormone therapy	Re-evaluation	Refused	08-05-2023
Forxiga	dapagliflozin	AZC	Diabetic nephropathy	New indication	Refused	02-05-2023
Invokana	canagliflozin	Janss. Inc	Diabetic nephropathy and cardiovascular events	New indication	Refused	02-05-2023
Tivicay	dolutegravir	ViiV	HIV	Listing request	Refused	01-05-2023
Bridion	sugammadex	Merck	Securing	Re-evaluation	Refused	20-04-2023
Tibella	tibolone	BioSynt	Hormone therapy	Listing request	Accepted	02-02-2023
Duavive	estrogen / bazedoxifene	Pfizer	Hormone therapy	Listing request	Refused	02-02-2023
<u>Avsola</u>	infliximab	Amgen	Ulcerative colitis	New indication	Accepted - Evaluated	01-02-2023
<u>Renflexis</u>	infliximab	Organon	Ulcerative colitis	New indication	Accepted - Evaluated	01-02-2023
<u>Inflectra</u>	infliximab	Pfizer	Ulcerative colitis	New indication	Accepted - Evaluated	01-02-2023
<u>Yescarta</u>	axicabtagene ciloleucel	Gilead	LGCB	Re-evaluation	Accepted - Evaluated	26-01-2023
<u>Kymriah</u>	tisagenlecleucel	Novartis	LLA	Re-evaluation	Accepted - Evaluated	26-01-2023
<u>Kymriah</u>	tisagenlecleucel	Novartis	LGCB	Re-evaluation	Accepted - Evaluated	26-01-2023